Biosystemix Ltd.

Building the bridge to Personalized Medicine

Biosystemix was founded by Dr. Roland Somogyi and Dr. Larry D. Greller to transform clinical and molecular disease research into data-driven medical solutions.  In addition to the vast amounts of medical patient information being used today, modern molecular profiling methods provide detailed data on the state and causes of an individual’s disease to an unprecedented degree.  Through the molecular analysis of blood and biopsy tissue, we can access the information that will tell us with increasing precision what a patient’s disease outcome might be, and which therapeutic strategies may be most suitable.

At Biosystemix we believe that patients and clinical practitioners should be able to benefit from these novel molecular and personalized medicine technologies as soon as possible.  These technologies are not only expected to lead to intensely needed increases in medical treatment successes and patient quality of life, but also to a reduction of the medical care burden, and more efficient, individually-targeted therapeutic development.

While there are many clinical molecular disease studies ongoing today, we are still challenged with bridging the substantial gap between the acquired medical research data, and the desired clinical, personalized medicine applications.  The key to information-driven, personalized medicine lies in developing accurate, powerful, and reliable computational and statistical predictive models from the evidence-base of molecular and clinical patient data.  These models, whether relatively simple or highly complex, can transform diagnostic, prognostic, and therapeutic decision-making.  Because they capture in detail the true clinical and molecular knowledge available, they maximize the predictive power available today for medical decision support.

Biosystemix provides the technologies, data analysis services, and partnering solutions to build the bridge between molecular and clinical study data and effective personalized medicine application models.  Our efficient and direct, data-driven approaches rely on advanced methods from statistics, signal processing, machine learning, pattern recognition, data mining, and mathematical modeling.  Our work is carefully orchestrated with biomedical domain expertise to guide the definition and search for effective applications.  Biosystemix currently provides its expertise in the form of consulting, analysis services, discovery partnerships, and reports focusing on complex predictive models for customer applications.  Together with our partners we are developing novel solutions that combine biomarkers and therapeutics into personalized medicine application solutions.

Biosystemix, Ltd.  ©  2007